Literature DB >> 15900607

Total loss of MHC class I is an independent indicator of good prognosis in breast cancer.

Zahra Madjd1, Ian Spendlove, Sarah E Pinder, Ian O Ellis, Lindy G Durrant.   

Abstract

Tumours can be recognised by CTL and NK cells. CTL recognition depends on expression of MHC Class I loaded with peptides from tumour antigens. In contrast, loss of MHC Class I results in NK activation. In our study a large set of samples from patients with primary operable invasive breast cancer was evaluated for the expression of MHC Class I heavy and light by immunohistochemical staining of 439 breast carcinomas in a tissue microarray. Forty-seven percent (206 of 439) of breast carcinomas were considered negative for HLA Class I heavy chain (HC10), whereas lack of anti-beta2m-antibody staining was observed in 39% (167 of 424) of tumours, with only 3% of the beta2m-negative tumours expressing detectable HLA Class I heavy chain. Correlation with patient outcome showed direct relationship between patient survival and HLA-negative phenotype (log rank = 0.004). A positive relationship was found between the intensity of expression of MHC Class I light and heavy chains expression and histological grade of invasive tumour (p < 0.001) and Nottingham Prognostic Index (p < 0.001). To investigate whether HLA Class I heavy and light chains expression had independent prognostic significance, Cox multivariate regression analysis, including the parameters of tumour size, lymph node stage, grade and intensity of HC10 and anti-beta2m staining, was carried out. In our analysis, lymph node stage (p < 0.001), tumour grade (p = 0.005) and intensity of MHC Class I light and heavy chains expression were shown to be independent prognostic factors predictive of overall survival (p-values HC10 = 0.047 and beta2m = 0.018).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15900607     DOI: 10.1002/ijc.21163

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  49 in total

1.  Prognostic significance of HLA class I expressing in gastric carcinoma defined by monoclonal anti-pan HLA class I antibody, EMR8-5.

Authors:  Hae-Wan Lee; Soo Kee Min; Young-Su Ju; Joohon Sung; Man Sup Lim; Dae Hyun Yang; Bong Hwa Lee
Journal:  J Gastrointest Surg       Date:  2011-04-22       Impact factor: 3.452

2.  HLA class I molecules partner with integrin β4 to stimulate endothelial cell proliferation and migration.

Authors:  Xiaohai Zhang; Enrique Rozengurt; Elaine F Reed
Journal:  Sci Signal       Date:  2010-11-23       Impact factor: 8.192

3.  Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study.

Authors:  Miao Yu; Yun-Hong Wang; Ahmed M E Abdalla; Wen-Qi Liu; Fei Mei; Jian Wang; Chen-Xi Ouyang; Yi-Qing Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-10-16

4.  Characterization of signaling function and expression of HLA class I molecules in medulloblastoma.

Authors:  Courtney Smith; Mariarita Santi; Elisabeth J Rushing; Robert Cornelison; Tobey J MacDonald; Stanislav Vukmanovic
Journal:  J Neurooncol       Date:  2010-09-02       Impact factor: 4.130

5.  Novel patterns of genome rearrangement and their association with survival in breast cancer.

Authors:  James Hicks; Alexander Krasnitz; B Lakshmi; Nicholas E Navin; Michael Riggs; Evan Leibu; Diane Esposito; Joan Alexander; Jen Troge; Vladimir Grubor; Seungtai Yoon; Michael Wigler; Kenny Ye; Anne-Lise Børresen-Dale; Bjørn Naume; Ellen Schlicting; Larry Norton; Torsten Hägerström; Lambert Skoog; Gert Auer; Susanne Månér; Pär Lundin; Anders Zetterberg
Journal:  Genome Res       Date:  2006-12       Impact factor: 9.043

6.  HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.

Authors:  María A Garrido; Teresa Rodriguez; Svitlana Zinchenko; Isabel Maleno; Francisco Ruiz-Cabello; Ángel Concha; Nicolás Olea; Federico Garrido; Natalia Aptsiauri
Journal:  Immunogenetics       Date:  2018-08-25       Impact factor: 2.846

7.  A novel role of HLA class I in the pathology of medulloblastoma.

Authors:  Courtney Smith; Mariarita Santi; Bhargavi Rajan; Elisabeth J Rushing; Mi Rim Choi; Brian R Rood; Robert Cornelison; Tobey J MacDonald; Stanislav Vukmanovic
Journal:  J Transl Med       Date:  2009-07-12       Impact factor: 5.531

8.  Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy.

Authors:  M Shehata; A Mukherjee; S Deen; A Al-Attar; L G Durrant; S Chan
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

Review 9.  Breast tumor microenvironment: proteomics highlights the treatments targeting secretome.

Authors:  Shui-Tein Chen; Tai-Long Pan; Hsueh-Fen Juan; Tai-Yuan Chen; Yih-Shyan Lin; Chun-Ming Huang
Journal:  J Proteome Res       Date:  2008-02-22       Impact factor: 4.466

10.  CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours.

Authors:  Zahra Madjd; Ali Zare Mehrjerdi; Ali Mohammad Sharifi; Saadat Molanaei; Shahriar Zohourian Shahzadi; Mohsen Asadi-Lari
Journal:  Cancer Immun       Date:  2009-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.